|
15 Nov 2018 |
Boehringer Ingelheim and Epizyme Announce Worldwide Collaboration to Develop Novel Epigenetic Oncology Therapies
|
|
15 Nov 2018 |
Arena Pharmaceuticals and United Therapeutics Announce Global License Agreement for Ralinepag
|
|
15 Nov 2018 |
Mission Therapeutics and AbbVie Sign DUBs Collaboration in Alzheimer’s and Parkinson’s Disease
|
|
14 Nov 2018 |
Dragonfly Therapeutics Announces Expansion of its Strategic Collaboration with Celgene, Doubling the Number of Programs and Including Targets for Solid Tumor Indications
|
|
13 Nov 2018 |
DNAtrix and Valo Therapeutics Enter into Strategic Partnership to Develop Peptide-Coated Oncolytic Viruses for Treating Cancer
|
|
13 Nov 2018 |
MaxCyte Announces Research Agreement with Kite, a Gilead Company
|
|
13 Nov 2018 |
Medigene AG: Medigene Signs Exclusive License Agreement with Leiden University to Develop Novel T Cell Receptor
|
|
13 Nov 2018 |
Sobi™ to acquire Synagis® US rights from AstraZeneca - creates a platform for global growth
|
|
11 Nov 2018 |
BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company
|
|
09 Nov 2018 |
CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology
|
|
08 Nov 2018 |
Brooklyn ImmunoTherapeutics Acquires IRX Therapeutics
|
|
08 Nov 2018 |
Saniona signs option agreement with Initiator Pharma
|
|
07 Nov 2018 |
Regulus Announces Successful Restructuring of Sanofi Collaboration
|
|
06 Nov 2018 |
Immunic AG gains exclusive, worldwide rights to promising drug development program with novel target for treatment of inflammatory bowel disease
|
|
06 Nov 2018 |
Lilly and NextCure Announce Collaboration to Discover and Develop Novel Immuno-Oncology Medicines
|
|
05 Nov 2018 |
Grünenthal Acquires Global Rights for Qutenza
|
|
05 Nov 2018 |
Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease
|
|
05 Nov 2018 |
MEI Pharma and Kyowa Hakko Kirin Announce License Agreement to Develop and Commercialize ME-401 in Japan
|
|
05 Nov 2018 |
Abeona Therapeutics and REGENXBIO Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
|
|
02 Nov 2018 |
BioArctic’s partner AbbVie exercises its option to license the alpha-synuclein antibody portfolio for Parkinson’s Disease
|
|
02 Nov 2018 |
Embark and Novo Nordisk enter collaboration to discover novel therapeutics for obesity and metabolic disease
|
|
01 Nov 2018 |
Sanofi and Denali Therapeutics to develop treatments for neurological and inflammatory diseases
|
|
01 Nov 2018 |
MeiraGTx Announces Exclusive Licensing Agreement with National Institutes of Health for Gene Therapy Treatment for Sjögren’s Syndrome and Associated Xerostomia or Xerophthalmia
|
|
31 Oct 2018 |
Gilead Sciences and Tango Therapeutics Announce Strategic Collaboration to Develop Next-Generation Targeted Immuno-Oncology Therapies
|
|
31 Oct 2018 |
Strongbridge Biopharma plc Enters into Agreement for Novo Nordisk to Acquire the U.S. and Canadian Rights to MACRILEN™ (macimorelin)
|
